Financial agreement takes the pressure off for pSivida
18 September, 2002 by Pete YoungPorous silicon drug delivery company pSivida has received a multimillion dollar vote of confidence in its prospects from New York's GEM private equity group.
Biotech sector looking OK, say analysts
17 September, 2002 by Melissa TrudingerASX-listed biotechs released a flurry of final results last week, with most companies meeting expectations for expenditure, revenues and losses.
Chemeq touts study supporting chicken weight drug
16 September, 2002 by Melissa TrudingerAn independent study of a polymeric antimicrobial drug made by WA-based company Chemeq has demonstrated that it significantly increases weight gain in chickens compared with two leading antibiotics used as growth promoters.
StarLink found in locally-bound food
16 September, 2002 by Pete YoungTraces of the controversial genetically-engineered US corn StarLink have been found in Australia's food matrix.
Peptech celebrates as US anti-TNF patents secured
13 September, 2002 by Graeme O'NeillSydney biotech company and antibody specialist Peptech has secured a prize patent for its anti-TNF antibody technology in the United States, the world's most lucrative market.
EpiTan names ex-CSL czar as director
13 September, 2002 by Melissa TrudingerMelbourne-based EpiTan has appointed ex-CSL general manager Stanley McLiesh as a non-executive director.
GTG joins project to bring wallaby back from the brink
13 September, 2002 by Melissa TrudingerMelbourne biotech company Genetic Technologies has become the sponsor of one of Victoria's most endangered animals, the brush-tailed rock wallaby.
Agenix profits up as sales soar
13 September, 2002 by Pete YoungOne of Australia oldest biotechs, Agenix Ltd, has produced extraordinary across-the-board results on booming sales of its blood clot diagnostic and infant hygiene products.
Cytopia unveils new HQ
12 September, 2002 by Melissa TrudingerBrand new labs on the fifth floor of the Baker Medical Research Institute have become the new home for Melbourne biotech company Cytopia.
Contract business boosts Progen revenue
12 September, 2002 by Pete YoungProgen Industries has posted a 58 per cent year-on-year revenue gain, due largely to the performance of its life sciences business, particularly its contract drug manufacturing unit.
Peplin rights issue bucks the trend
12 September, 2002 by Pete YoungListed company Peplin Biotech is proving that requests for fresh funds by young biotechs whose products are far from market-ready aren't receiving an automatic thumbs down from investors.
Axon posts loss as revenue slumps
12 September, 2002 by Pete YoungFormer share market favorite Axon Instruments has posted after-tax losses of $8.8 million on falling revenues for the half year to June 30.
Bio-septic system offers relief for the effluent society
11 September, 2002 by Graeme O'NeillOut of sight, out of mind, and far too often, out of order - that malodorous monster, the septic tank, lurks just below the ground in the back yards of more than 450,000 homes around Australia's eastern seaboard, from Queensland to Victoria. Another 200,000 households around New Zealand are unsewered.
Benitec hires management, gears up to commercialise
11 September, 2002 by Melissa TrudingerBrisbane biotech Benitec has added a managing director and a commercial director to its senior management team, as it prepares to expand its commercialisation activities.
New deal suggests FDA approval closer for Gradipore
11 September, 2002 by Iain ScottFDA approval for Sydney-based separation technology company Gradipore has come a step closer, after the signing of a new agreement with Canadian hyperimmune product specialist Cangene.
